Received Feb 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 2 | FC3180 | IM / AR |
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 3 | FE3590 | IM / AR |
| COVID19 | COVID19 (COVID19 (UNKNOWN)) | UNKNOWN MANUFACTURER | 1 | 1805029 | IM / AR |
JANSSEN 3/10/2021 PFIZER 8/20/2021 PFIZER 10/21/2021 DEVELOPED AXILLARY ADENOPATHY OF IN THE AXILLA THAT NEVER COMPLETELY RESOLVED PROMPTED CHEST CT IN 2022 UNREMARKABLE. MID 2025 DEVELOPED ATCP AND MILD DOE AND ORTHOPNEA AND IN LATE 2025 AND 2026 DIAGNOSED WITH COVID-19 VACCINE MYOPERICARDITIS REQUIRING ONE PERICARDIOCENTESIS AND HAS HAD MULTIPLE PLEUROCENTESIS. SPIKE ABS > 20,000. FLUID REPORTED TO BE NON BLOODY, NEGATIVE FOR INFECTION, NEGATIVE FOR MALIGNANCY. ECHOCARDIOGRAPHY REPORTED NL LVEF. TREATED WITH COLCHICINE AND EMPIRIC DOXYCYCLINE AND WHEN STABILIZED WITH BE TREATED WITH PROTOCOL BASE SPIKE DETOXIFICATION.
EXAM, ECG, LABS, ECHOCARDIOGRAPHY, CHEST CT, CHEST X-RAY